IMUNON reports improved cancer drug trial results, posts narrower loss
Tweet Send to a Friend
IMUNON Inc. (NASDAQ: IMNN) reported a net loss of $14.5 million for 2025, compared to $18.6 million in 2024, while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
